| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04900766 Details | 2024-03-07 Interventional | 1 | 31 | Mitoxantrone Sarcoma Unresectable or… | The sponsor has adjusted its R&D strategy. - | |||
| NCT04718402 Details | 2024-03-07 Interventional | 1 | 21 | Mitoxantrone Carcinoma Stomach Neoplas… Advanced Gastri… | The sponsor has adjusted its R&D strategy. - | |||
| NCT04718376 Details | 2024-03-07 Interventional | 1 | 56 | Mitoxantrone Carcinoma, Ovar… Ovarian Neoplas… Platinum-resist… | The sponsor has adjusted its R&D strategy. - | |||
| NCT04548700 Details | 2024-03-07 Interventional | 1 | 38 | Cyclophosphamid… Mitoxantrone Prednisone Vincristine Lymphoma, T-Cel… Peripheral T Ce… Treatment-naïv… | The sponsor has adjusted its R&D strategy. - | |||
| NCT04509466 Details | 2024-03-07 Interventional | 1/2 | 41 | Asparaginase Mitoxantrone Pegaspargase Lymphoma, Extra… Extranodal NK/T… | The sponsor has adjusted its R&D strategy. - | |||
| NCT03973333 Details | 2024-03-07 Interventional | 1/2 | 75 | Atezolizumab Select Advanced… | The Sponsor terminated the study and there is no further enrollment. Endpoints will not be
assessed for this trial. - | |||
| NCT02498977 2014-004557-14 Details | 2024-03-07 Interventional | 4 | 116 | Azathioprine Cyclosporine Cyclosporins Mycophenolic Ac… Tacrolimus Transplantation… | Primary endpoint not reached. - | |||
| NCT05807126 Details | 2024-03-06 Interventional | 1 | - | Magrolimab Olaparib Poly(ADP-ribose… Prostatic Neopl… Anatomic Stage … Castration-Resi… Stage IVB Prost… | Added per CS0161016, see memo uploaded to trial related documents. - | |||
| NCT05536882 Details | 2024-03-06 Interventional | 3 | 0 | Adapalene Benzoyl Peroxid… Molluscum Conta… | The original PI left the institution prior to final IRB approval and the remaining study team
did not have the resources to continue. - | |||
| NCT05005507 2021-002450-81 Details | 2024-03-06 Interventional | 2 | 1 | Peginterferon a… Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Herpesviridae I… Virus Diseases | A strategic decision was made to not further execute the study. This decision was not based on
a safety concern. Only 1 participant was enrolled in the study in Arm 1. Participants were also planned to be enrolled in Arms 2 and 3 but were not enrolled as the study terminated prematurely based on a strategic decision and not for safety reasons. | |||
| NCT04609046 Details | 2024-03-06 Interventional | 1 | - | Antibodies Antibodies, Mon… Antineoplastic … Immunoglobulins Lenalidomide Methotrexate Nivolumab Rituximab Lymphoma Lymphoma, Large… Primary Diffuse… | Other - Awaiting amendment approval - | |||
| NCT04340843 Details | 2024-03-06 Interventional | 2 | - | Azacitidine Belinostat Decitabine Decitabine and … Guadecitabine Chondrosarcoma Locally Advance… Metastatic Prim… Unresectable Pr… | Other - Completed stage 1 accrual - | |||
| NCT05915286 Details | 2024-03-05 Interventional | 4 | - | Chlorthalidone Furosemide Kidney Failure,… End Stage Renal… | Personnel/staffing issues. - | |||
| NCT05845008 Details | 2024-03-05 Interventional | 3 | 0 | Acetaminophen Naproxen Orthodontic Pai… | The study is no longer required due to change in development program strategy. - | |||
| NCT05564416 Details | 2024-03-05 Interventional | 2 | 0 | Antibodies, Mon… Atezolizumab Carcinoma Carcinoma, Tran… Urinary Bladder… Bladder Carcino… Bladder Urothel… Muscle Invasive… Renal Pelvis an… Stage II Bladde… Stage III Bladd… Stage IVA Bladd… Urothelial Carc… | Feasibility issues per Complete Sheet - | |||
| NCT05552157 Details | 2024-03-05 Interventional | 2/3 | - | Antibodies, Mon… Alzheimer Disea… Dementia Alzheimers Dise… Alzheimers Dise… | Roche announced a decision to discontinue most of the company's global trials of gantenerumab.
The DIAN-TU has paused the DIAN-TU-002 Primary Prevention Trial related to gantenerumab while
considering other potential options for this platform trial. - | |||
| NCT05223673 2021-003151-41 Details | 2024-03-05 Interventional | 3 | 7 | Trifluridine Colorectal Neop… Metastatic Colo… | Sponsor decided to discontinue the study during the Lead-In part and the Phase III part was not
started due to strategic reasons. - | |||
| NCT04816214 2020-003677-21 Details | 2024-03-05 Interventional | 3 | 6 | Carboplatin Osimertinib Pemetrexed Carcinoma, Non-… | Novartis decided to terminate the study based on a business consideration and not related with
any safety concerns. Randomized part was not initiated - | |||
| NCT03871348 2017-004766-94 Details | 2024-03-05 Interventional | 1 | 77 | Cemiplimab Neoplasm Metast… Metastatic Neop… | Sponsor terminated the study for non-safety reasons - | |||
| NCT03341962 2017-003703-22 Details | 2024-03-05 Interventional | 2 | 263 | Calcium Colitis Colitis, Ulcera… Ulcer Ulcerative Coli… | Considering the efficacy results of the induction phase (allowed use of corticosteroids as
concomitant medication) in the study population and since IMU-838 did not show superiority over
placebo, the OLE was prematurely closed by the sponsor. - |